OMC · Q1 2026 Earnings

Cautious

Omnicom Group

Reported April 28, 2026

30-second summary

Omnicom's first full quarter as the merged entity printed $6.24B revenue (+69.1% reported YoY), 3.9% organic growth on the core (retained-portfolio) base, and 14.8% adjusted EBITA margin on core operations ($833.5M) — landing the integration story roughly where the March investor day framed it. Non-GAAP EPS of $1.90 grew 11.8% YoY, at the low end of the "double-digit" FY guide, with management indicating later quarters will run "higher double digits." The quieter signal: the FY FX tailwind was cut from "in excess of 2%" to "approximately 1%," advertising revenue is shrinking inside the new portfolio, and the 2026 EPS bridge now leans harder on the first explicit $3.5B in-year repurchase target (vs the prior $2.5B ASR + open-market framing under the unchanged $5.0B authorization) than on revenue acceleration.

Headline numbers

EPS

Q1 FY2026

$1.90

Revenue

Q1 FY2026

$6.24B

+69.1% YoY

Operating margin

Q1 FY2026

10.4%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$6.24B	+69.1%	$5.53B	+12.9%
EPS	$1.90	—	$2.59	-26.6%
Operating margin	10.4%	—	-17.7%	+2810bps

Guidance

Company narrowed FX tailwind assumptions but raised shareholder return targets (buyback +$1.0B, share count reduction +1-2 pts) while reaffirming cost synergy and organic growth guidance.

Guidance is issued for both next quarter and the full year. Both may appear below.

New guidance

Metric	Period	Guide	YoY
tax rate	FY 2026	26%	—
Organic growth expectation	FY 2026	4% constant currency growth	—
EPS growth guidance	FY 2026	double-digit, with later quarters expected to be higher double digits	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Net interest expense increase	FY 2026	approximately $210 million vs 2025	approximately $200 million vs 2025	-$10 million (4.8% reduction in interest headwind)	Lowered
Share count decline	FY 2026	9% to 11% reduction by end of 2026; 7% to 8% weighted average reduction	11% to 12% by December 31, 2026; 8% to 9% weighted average	+1 to 2 pts on end-of-year reduction; +1 pt on weighted average	Raised
FX benefit to reported revenue	FY 2026	in excess of 2% revenue benefit	approximately 1%	-1+ percentage points (from >2% to ~1%)	Lowered
Share repurchases	FY 2026	$5.0 billion authorization, $2.5 billion ASR launched	$3.5 billion in 2026 under $5.0 billion authorization	+$1.0 billion ($2.5B ASR baseline to $3.5B total 2026 execution)	Raised
Weighted average shares outstanding decline	FY 2026	7% to 8% weighted average reduction	8% to 9% for the year	+1 percentage point	Raised

Reaffirmed unchanged this quarter: Cost reduction synergies ($900 million in 2026)

Platform metrics

Q1 FY2026

Segment	Q1 FY2026
Organic Revenue Growth (Core Operations)	3.9%
Non-GAAP Adjusted EPS Growth	+11.8%
Foreign Currency Translation Impact	+2.7% (Core Operations)

Profitability

Q1 FY2026

Segment	Q1 FY2026
Adjusted EBITA Margin (Core Operations)	14.8%
Non-GAAP Adjusted EBITA	$861.4 million
Operating Income Margin	10.4%

Management tone

IPG announcement framing → Defensive floor-protection (Q2 2025) → AI + synergy upside (Q3 2025) → Transformation & capital return (Q4 2025) → Operating model execution (Q1 FY2026)

The integration narrative has compressed from "two companies" to "one operating model" in five months. Q4 2025 brought the brand consolidation announcement; this quarter management cited 20+ agency brands already merged or sunset, alongside named new wins (IBM, GSK, John Deere, Little Caesars, Acadia Pharmaceuticals, Bailey's). Management's prepared-remarks framing — that the integrated approach is making it easier for clients to access all their marketing and sales needs from a single partner — is the deal thesis being validated in real time. The pace of brand consolidation in one quarter post-close is more aggressive than any agency holding-company precedent.

Confidence has shifted from organic growth re-acceleration to financial-engineering execution. Across 2025 the bull case rested on combined-entity revenue synergy and growth re-acceleration. This quarter, with Q1 organic at 3.9% versus a 4% FY target and FX tailwind halved, the bridge to "higher double-digit" EPS in later quarters rests on (a) front-loaded $900M cost synergies, (b) the $3.5B in-year buyback execution, and (c) margin leverage from disposing of sub-scale businesses. The narrative is no longer "we'll grow faster combined"; it's "we'll deliver double-digit EPS through cost-out and float compression while the portfolio resets."

Disclosure framework upgrade. The explicit framing of core vs. total operations, the willingness to size the FX cut rather than bury it, and the formal "core operations" reporting slide are all unusual disclosure quality for Omnicom. Read this as management knowing the 2026 story will require multi-metric tracking and front-loading the disclosure framework while there's still credibility from the investor day to spend.

Recurring themes management leaned on this quarter:

Rapid integration execution and synergy realizationShift to integrated media and AI-first operating modelPortfolio optimization through disciplined divestituresWins in multi-service, multi-year client relationshipsAgentic AI deployment shortening media supply chainEPS accretion through share repurchase and synergy capture

Risks management surfaced:

Geopolitical uncertainty in Middle East (less than 2.5% of revenue but creating unpredictable impact)Competitive pricing pressure from peers gaining momentumFX headwinds if current rates don't hold (offset by 1% assumed benefit)Execution risk on remaining $2.2B in asset dispositionsIntegration complexity across 20+ merged agency brands

Answers to last quarter's watch list

March 12 investor day — does management quantify a 2026 revenue and EBITDA range? The investor day delivered the framework (4% constant-currency organic, $1.5B synergies with $900M in 2026, $5B authorization) and this Q1 print fills in the rest — 26% tax rate, double-digit EPS guidance, $3.5B in-year buyback execution. No explicit revenue dollar range or EBITDA margin range was issued, but the operating algorithm is now quantified across enough line items to model.

Resolved positively

$900M synergy capture pace in H1 2026 — Adjusted EBITA margin on the core printed 14.8% in Q1, which management cited as +240bps versus the prior-year combined basis. That's meaningful sequential cost compression and consistent with front-loaded synergy capture. The $900M target was reaffirmed without hedging.

Resolved positively

Pace of $3.2B revenue repositioning program — Management has formalized "core operations" reporting that excludes planned dispositions. ~$1B was disposed in Q1 FY2026, leaving ~$2.2B remaining. The 3.9% organic figure is on the core base. Disclosure framework is in place but proceeds and timing remain open.

Continue monitoring

ASR settlement and remaining buyback execution — Management disclosed an explicit $3.5B 2026 calendar-year repurchase target (under the unchanged $5.0B authorization), with end-of-year share count reduction lifted to 11–12% (from 9–11%) and weighted-average to 8–9% (from 7–8%). $2.8B was already repurchased through Q1 via ASR and open-market activity.

Resolved positively

Whether retained-portfolio organic growth becomes a standing disclosure — Yes. Core operations organic growth (3.9% this quarter) is now the disclosed headline metric, with planned dispositions explicitly excluded. The disclosure framework is consistent with what was previewed at Q4. Peer comparability against Publicis and WPP is partially restored but the base differs from legacy Omnicom.

Resolved positively

Net interest expense trajectory vs the $210M guide — Net interest expense FY guide narrowed slightly to ~+$200M (from ~+$210M), a modest favorable revision suggesting refinancing on the $1.4B April 2026 maturity came in better than book or commercial paper costs are below model. Not a material swing but the direction is positive.

Resolved positively

What to watch into next quarter

Whether Q2 core organic growth accelerates above 4% to validate the FY target — Q1 printed 3.9% on the core, just below the FY ~4% constant-currency target. A Q2 sub-4% print with FX tailwind narrowing through the year would force management to either lower the FY target or lean harder on H2 acceleration narrative. A Q2 above 4.5% would re-establish revenue as a credible lever alongside cost-out and buybacks.

Advertising discipline trajectory — is Q1's decline structural or transitional? Advertising at $943M (16.8% of core) was the only discipline to decline. If Q2 advertising remains negative while Integrated Media continues at high-single-digit growth, the strategic reshaping toward Integrated Media majority is happening through Advertising shrinkage rather than Integrated Media expansion — a less attractive growth algorithm than the investor-day framing implied.

Q2 EBITA margin progression — With the buyback adding ~1 pt to EPS progression mechanically, Q2 operating leverage needs to deliver another 100–150bps of core EBITA margin expansion (from 14.8%) to make the back-half math work. Watch salary-and-related as % of revenue.

Remaining disposition pace and proceeds disclosure — ~$2.2B of dispositions remain after the ~$1B already completed in Q1 FY2026. The proceeds multiple disclosed at sale is the key value-creation tell. Q2 should bring further named transactions.

Whether FX guidance narrows further — Q1 printed +2.7% FX on the core; the FY guide is now ~1%, implying flat-to-negative FX in H2. If FY FX cuts again at Q2, the cumulative reported-revenue revision since Q4 will exceed $250M — a quiet headwind worth tracking against the reaffirmed organic target.

Sources

Omnicom Group Q1 FY2026 Earnings Release, filed with the SEC: https://www.sec.gov/Archives/edgar/data/29989/000002998926000008/a2026q1earningsrelease.htm
Omnicom Group Q1 FY2026 earnings call (prepared remarks)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.